Here’s a bold statement: Malaysia has just unlocked a staggering RM1 billion in savings, and it’s all thanks to a simple yet transformative shift in how the government procures medications. But here’s where it gets controversial—Prime Minister Anwar Ibrahim is challenging the long-held belief that expensive, brand-name drugs from the US and Europe are the only way to ensure quality healthcare. In a recent address at the launch of a new hospital block in Seberang Jaya, Anwar revealed that the government’s decision to prioritize generic drugs over costly originator medicines has saved the country nearly RM1 billion in just two years. This move, he argues, should have been made decades ago, as it allows Malaysia to access equally effective medications at a fraction of the cost from countries like India, Turkey, Brazil, and China.
Anwar didn’t hold back, stating, ‘We’ve wasted tens of billions of ringgit chasing the prestige of expensive pills from the US, where a single tablet can cost RM100, when we could have gotten the same treatment for RM10 elsewhere.’ He emphasized that Malaysia should no longer cling to the outdated notion that higher prices equate to better care. ‘We’re breaking free from the mindset that expensive medications from Western countries are something to boast about,’ he added.
And this is the part most people miss—the shift to generic drugs isn’t just about cost savings; it’s about rethinking the entire healthcare system. Health Minister Dzulkefly Ahmad reinforced this during a press conference, stating that generic drugs are just as safe and effective as their brand-name counterparts. He noted that the ‘generic-first’ policy has already led to widespread adoption by doctors in public health facilities, saving over RM900 million in the past two years alone—a figure expected to grow.
But Anwar didn’t stop at healthcare costs. He also took aim at the snail-paced construction of public health infrastructure, pointing out that projects like the Seberang Jaya hospital, which began in 2016, took nearly a decade to complete. ‘We need to learn from these delays,’ he urged, calling for faster land approvals and more efficient processes. ‘Hospital construction shouldn’t drag on for years while people wait for essential services.’ Dzulkefly echoed this sentiment, revealing that some projects in Sabah and Sarawak have faced delays of up to a decade, and he’s now leading a committee to address these ‘sick’ projects nationwide.
Here’s the controversial question: Is Malaysia’s healthcare system finally prioritizing practicality over prestige? And if so, why did it take so long? Anwar’s bold move to embrace generic drugs and streamline infrastructure projects is undeniably transformative, but it also raises questions about past inefficiencies. What do you think? Is this the right direction, or are there risks to this approach? Share your thoughts in the comments—let’s spark a conversation about the future of healthcare in Malaysia.
